Brief: Inhibikase Therapeutics Announces Development Of Novel Formulation Of Risvodetinib
24/08/2023 13:33
Aug 24 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DEVELOPMENT OF NOVEL
FORMULATION OF RISVODETINIB
* INHIBIKASE THERAPEUTICS INC - TABLET FORMULATION TO BE
EVALUATED
IN PLANNED 12-MONTH EXTENSION PORTION OF 201 TRIAL
Source text for Eikon: ID:nPn33tFppa
Further company coverage: IKT.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share